Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides

US12117454B2 · kind B2 · utility

Assignee

• Roche Diagnostics Operations, Inc. · US

Inventors

• Dirk Block · Bichl, DE
• Hans-Peter Brunner · Münchenstein, CH
• Ursula-Henrike Wienhues-Thelen · Krailling, DE
• Christian Zaugg · Rheinfelden, CH
• Thomas Dieterle · Freiburg (Elbe), DE
• Cheryl R. Mitchell · Stockton, US
• Johan Ubby · Zug, CH
• Sandra Sanders-van Wijk · Eijsden, NL

Key dates

• Filing date: May 7, 2020
• Grant date: Oct 15, 2024
• Expiry date: Nov 9, 2041

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Methods for identifying a patient who is eligible for an intensification of heart failure therapy are disclosed. Furthermore, methods for optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy are disclosed. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described methods.